Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 86
Filter
1.
Cancer Prev Res (Phila) ; 15(11): 777-784, 2022 11 01.
Article in English | MEDLINE | ID: mdl-35969832

ABSTRACT

The human papillomavirus (HPV) vaccine was indicated for the prevention of vulvovaginal cancers in 2008, but its impact on the incidence of vulvar cancers within the US is unknown. To determine this, we conducted a secondary analysis of 88,942 vulvar cancer cases among women 20+ years old using the US Cancer Statistics 2001-2018 databases. Data were stratified by tumor behavior (in situ or invasive), age (20-44, 45-64, 65+ years old), race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic), and US census region (Northeast, South, Midwest, West), and incidence rates and average annual percentage changes (AAPC) were calculated by group. Reversing previous trends, the incidence of vulvar carcinoma in situ significantly decreased between 2001 and 2018 among women from all age groups, races/ethnicities, and regions (combined AAPC,  -4.3; 95% confidence interval (CI), -4.7 to -3.8). The incidence of invasive vulvar squamous cell carcinoma decreased significantly among 20- to 44-year-old women (AAPC, -0.8; 95% CI, -1.3 to -0.3), but significantly increased among those 45 to 64 (AAPC, 2.3; 95% CI, 1.8-2.8) and 65+ years old (AAPC, 1.2; 95% CI, 1.1-1.4). Regardless of tumor behavior, incidence was highest among non-Hispanic Whites and the Midwest region. Overall, the significant declines in vulvar carcinoma in situ among all ages, as well as invasive vulvar cancer among younger women, are encouraging and complement other recent data suggesting HPV vaccinations are already reducing anal and cervical cancer incidence. Over time, further declines in vulvar carcinoma incidence are likely as uptake and completion rates of the HPV vaccine increase in the US. PREVENTION RELEVANCE: We found evidence that HPV vaccinations likely contributed to a decrease in the incidences of vulvar carcinoma in situ and invasive vulvar carcinoma among 20- to 44-year-old women between 2001 and 2018. Our data add to the growing evidence that HPV vaccinations are reducing the incidence of HPV-related anogenital cancers.


Subject(s)
Alphapapillomavirus , Carcinoma in Situ , Papillomavirus Infections , Papillomavirus Vaccines , Uterine Cervical Neoplasms , Vulvar Neoplasms , United States/epidemiology , Female , Humans , Young Adult , Adult , Vulvar Neoplasms/epidemiology , Vulvar Neoplasms/prevention & control , Vulvar Neoplasms/complications , Papillomavirus Vaccines/therapeutic use , Incidence , Papillomavirus Infections/complications , Papillomavirus Infections/epidemiology , Papillomavirus Infections/prevention & control , Uterine Cervical Neoplasms/epidemiology , Uterine Cervical Neoplasms/prevention & control , Uterine Cervical Neoplasms/pathology , Carcinoma in Situ/epidemiology , Carcinoma in Situ/prevention & control , Vaccination
4.
J Womens Health (Larchmt) ; 30(12): 1667-1672, 2021 12.
Article in English | MEDLINE | ID: mdl-34871035

ABSTRACT

Human papillomavirus (HPV) infections cause more than 35,900 cancers annually in the United States. Although cervical cancer is the most prevalent HPV-related malignancy in women, the virus is also responsible for a significant percentage of anal, vaginal, and vulvar cancers. A comprehensive approach to mitigating cervical cancer includes HPV vaccination (primary prevention), screening and treatment of precancerous lesions (secondary prevention), and diagnosis and treatment of invasive cancer (tertiary prevention). Although a successful strategy, there are opportunities to innovate and increase access that can also be adapted to address the unique clinical care gaps that exist with the other anogenital cancers. The Society for Women's Health Research held a series of interdisciplinary meetings and events, during which expert researchers, clinicians, patient advocates, and health care policy leaders evaluated the current landscape of HPV-related cancers and their effects on women's health. This report summarizes the discussions of this working group and areas it identified in which to address gaps in primary and secondary prevention approaches to improve access and health outcomes for women with HPV-related anogenital cancers.


Subject(s)
Alphapapillomavirus , Papillomavirus Infections , Papillomavirus Vaccines , Uterine Cervical Neoplasms , Vulvar Neoplasms , Female , Humans , Papillomaviridae , Papillomavirus Infections/diagnosis , Papillomavirus Infections/prevention & control , United States/epidemiology , Uterine Cervical Neoplasms/diagnosis , Uterine Cervical Neoplasms/prevention & control , Vulvar Neoplasms/diagnosis , Vulvar Neoplasms/prevention & control
6.
Acta Med Port ; 33(3): 198-201, 2020 Mar 02.
Article in English | MEDLINE | ID: mdl-32130098

ABSTRACT

INTRODUCTION: Human papillomavirus is responsible for almost all cases of cervical cancer, an important portion of anogenital and oropharyngeal invasive and preinvasive lesions, as well as genital warts (condyloma acuminatum) and recurrent respiratory papillomatosis. Currently, three prophylactic vaccines against high-risk Human papillomavirus are commercialized in many countries worldwide. METHODS: To this non-systematic review the authors searched in MEDLINE/PubMed for systematic reviews, meta-analysis and randomized controlled trials, published in the last six years, using the terms "HPV", "non-cervical cancer" and "vaccine". Non-cervical cancers caused by human papillomavirus are less common lesions. However, its incidence has been increasing, while cervical cancer has declined, due mainly to highly effective screening programs. There are no formal screening programs for non-cervical cancers, so universal vaccination could have an important impact. The preventive effect of the vaccine is mainly studied and established in relation to cervical cancer, although it has also been demonstrated in the development of vulvar and vaginal lesions. To date, the efficacy in preventing anal and oropharyngeal diseases related with human papillomavirus is uncertain due to scarce supporting data and low vaccination coverage in men. The prevalence of injuries and subsequent absolute benefit of vaccination is lower in men, but it provides an additional benefit to the herd immunity achieved with the vaccination of women. CONCLUSION: The total fraction of malignant and pre-malignant lesions attributed to Human papillomavirus genotypes contained in the nonavalent vaccine is significant in both women and men, which turns this vaccine into a great asset in terms of Public Health.


Introdução: O vírus do papiloma humano é responsável por quase todos os casos de cancro do colo do útero, de uma importante fração de lesões anogenitais e orofaríngeas pré-invasivas e invasivas bem como de condilomas genitais e da papilomatose respiratória recorrente. Atualmente existem três vacinas profiláticas contra o vírus do papiloma humano de alto risco comercializadas em vários países do mundo. Métodos: Para esta revisão não-sistemática, os autores pesquisaram na MEDLINE/PubMed revisões sistemáticas, metanálises e ensaios clínicos randomizados, publicados nos últimos seis anos, utilizando os termos "HPV", "cancro não cervical" e "vacina". Os cancros não cervicais causados pelo vírus do papiloma humano são lesões menos comuns. Contudo, a sua incidência tem aumentado, a par de uma diminuição do cancro do colo do útero, devido principalmente à implementação de programas de rastreio altamente eficazes. Uma vez que não existem programas oficiais de rastreio para cancros não cervicais, a vacinação universal pode ter um impacto importante. O efeito preventivo da vacina é principalmente estudado e estabelecido em relação ao cancro do colo do útero, embora também tenha sido demonstrado no desenvolvimento de lesões vulvares e vaginais. Até ao momento, a eficácia na prevenção de doenças anais e orofaríngeas relacionadas com o vírus do papiloma humano é incerta, devido à escassez de dados na literatura e baixa cobertura de vacinação em homens. A prevalência de lesões e o consequente benefício absoluto da vacinação é inferior nos homens, porém proporciona um benefício adicional à imunidade de grupo alcançada com a vacinação de mulheres. Conclusão: A fração total de lesões malignas e pré-malignas atribuídas aos genótipos de vírus do papiloma humano contidos na vacina nonavalente é significativa tanto em mulheres quanto em homens, o que confere a essa vacina um grande potencial em termos de Saúde Pública.


Subject(s)
Alphapapillomavirus , Neoplasms/prevention & control , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/administration & dosage , Precancerous Conditions/prevention & control , Alphapapillomavirus/genetics , Alphapapillomavirus/immunology , Anus Neoplasms/prevention & control , Anus Neoplasms/virology , Carcinoma, Squamous Cell/prevention & control , Carcinoma, Squamous Cell/virology , Female , Genotype , Head and Neck Neoplasms/prevention & control , Head and Neck Neoplasms/virology , Humans , Male , Neoplasms/virology , Oropharyngeal Neoplasms/prevention & control , Oropharyngeal Neoplasms/virology , Papillomavirus Infections/virology , Penile Neoplasms/prevention & control , Penile Neoplasms/virology , Precancerous Conditions/virology , Respiratory Tract Infections/prevention & control , Respiratory Tract Infections/virology , Sex Factors , Uterine Cervical Neoplasms/prevention & control , Uterine Cervical Neoplasms/virology , Vaginal Neoplasms/prevention & control , Vaginal Neoplasms/virology , Vulvar Neoplasms/prevention & control , Vulvar Neoplasms/virology
8.
Expert Rev Vaccines ; 18(11): 1157-1166, 2019 11.
Article in English | MEDLINE | ID: mdl-31718338

ABSTRACT

Introduction: Safety and efficacy of prophylactic HPV vaccines against HPV infection and associated cervical cancers and precursors is well documented in the literature; however, their efficacy against vulval and vaginal endpoints has not been previously assessed.Areas covered: Published results of trials involving licensed HPV vaccines were included. Main efficacy outcomes were histologically confirmed high-grade vulval and vaginal precancer distinguishing those associated with vaccine HPV types and any vulval and vaginal precancerous lesions. Exposure groups included women aged 15-26 or 24-45 years being initially negative for high-risk HPV (hrHPV), negative for the HPV vaccine types, and women unselected by HPV status.Expert opinion: Our results show that the HPV vaccines are equally highly efficacious against vulval/vaginal disease as previously noted for cervical disease. The vaccines demonstrated excellent protection against high-grade vulval and vaginal lesions caused by vaccine-related HPV types among young women who were not initially infected with hrHPV types or types included in the vaccines (vaccine efficacies more than 90%). No protection against high-grade vulval and vaginal lesions associated with HPV16/18 was observed for mid-adult women. Trials were not powered to address protection against invasive cancers.


Subject(s)
Papillomavirus Infections/complications , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/administration & dosage , Papillomavirus Vaccines/immunology , Precancerous Conditions/prevention & control , Vaginal Neoplasms/prevention & control , Vulvar Neoplasms/prevention & control , Adolescent , Adult , Female , Humans , Middle Aged , Treatment Outcome , Young Adult
9.
JAMA Netw Open ; 2(4): e190819, 2019 04 05.
Article in English | MEDLINE | ID: mdl-30977845

ABSTRACT

Importance: Human papillomavirus (HPV), particularly HPV type 16, causes most anal and vulvar high-grade squamous intraepithelial lesions (HSIL), which are precursors to cancer. After initial treatment of HSIL, more than 30% of patients will have disease recurrence, with even higher recurrence among HIV-positive individuals and men who have sex with men. Recurrences can be debilitating and lead to significant morbidity and medical expense. Observational studies suggest a possible therapeutic benefit of the licensed HPV vaccines in reducing recurrent lesions in previously infected persons. Objective: To test whether the licensed prophylactic HPV vaccine (Gardasil-9) can reduce the risk of HSIL recurrence by 50% in previously unvaccinated individuals recently treated for anal or vulvar HSIL. Design, Setting, and Participants: This is a trial protocol for a randomized, double-blind, placebo-controlled, proof-of-concept clinical trial. Eligible participants are aged 27 to 69 at study start and have not received prior HPV vaccination, have had anal or vulvar HSIL diagnosed on or after January 1, 2014, and have no evidence of HSIL recurrence at screening. Persons infected with HIV are eligible for the study provided they are receiving antiretroviral therapy. Target enrollment is 345 individuals. The primary outcome is time to histopathologically confirmed recurrence of HSIL. Differences in the risk for recurrence of HSIL will be evaluated using Cox proportional hazard models. Additional analyses include (1) frequency of HSIL recurrence; (2) role of HPV antibodies in deterring recurrence; (3) role of HPV persistence in recurrence, as measured by HPV genotype or HPV-16 variant lineage determined using swab samples collected at months 0, 18, and 36; and (4) incidence of adverse events. The study will be conducted at the University of Washington Virology Research Clinic from 2017 through 2022. Participants will be followed up for up to 36 months in the clinic, and up to 42 months by telephone. Discussion: Management of persistent or rapidly recurring anogenital HSIL remains challenging. Results from this study will provide evidence on whether incorporating the nonavalent HPV vaccine into routine care can decrease recurrence of anal and vulvar HSIL. Trial Registration: ClinicalTrials.gov identifier: NCT03051516.


Subject(s)
Anus Neoplasms/prevention & control , Neoplasm Recurrence, Local/prevention & control , Papillomavirus Vaccines/therapeutic use , Vulvar Neoplasms/prevention & control , Adult , Aged , Anus Neoplasms/pathology , Anus Neoplasms/virology , Double-Blind Method , Female , HIV Infections/complications , HIV Infections/immunology , HIV Infections/virology , Homosexuality, Male , Human papillomavirus 16/immunology , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/immunology , Neoplasm Recurrence, Local/pathology , Papillomaviridae/drug effects , Papillomaviridae/genetics , Papillomavirus Infections/complications , Papillomavirus Infections/immunology , Papillomavirus Infections/virology , Placebos/administration & dosage , Risk Factors , Squamous Intraepithelial Lesions/pathology , Vulvar Neoplasms/pathology , Vulvar Neoplasms/virology
10.
Sex Transm Infect ; 95(1): 28-35, 2019 02.
Article in English | MEDLINE | ID: mdl-30674687

ABSTRACT

BACKGROUND: Many economic evaluations of human papillomavirus vaccination should ideally consider multiple disease outcomes, including anogenital warts, respiratory papillomatosis and non-cervical cancers (eg, anal, oropharyngeal, penile, vulvar and vaginal cancers). However, published economic evaluations largely relied on estimates from single studies or informal rapid literature reviews. METHODS: We conducted a systematic review of articles up to June 2016 to identify costs and utility estimates admissible for an economic evaluation from a single-payer healthcare provider's perspective. Meta-analyses were performed for studies that used same utility elicitation tools for similar diseases. Costs were adjusted to 2016/2017 US$. RESULTS: Sixty-one papers (35 costs; 24 utilities; 2 costs and utilities) were selected from 10 742 initial records. Cost per case ranges were US$124-US$883 (anogenital warts), US$6912-US$52 579 (head and neck cancers), US$12 936-US$51 571 (anal cancer), US$17 524-34 258 (vaginal cancer), US$14 686-US$28 502 (vulvar cancer) and US$9975-US$27 629 (penile cancer). The total cost for 14 adult patients with recurrent respiratory papillomatosis was US$137 601 (one paper).Utility per warts episode ranged from 0.651 to 1 (12 papers, various utility elicitation methods), with pooled mean EQ-5D and EQ-VAS of 0.86 (95% CI 0.85 to 0.87) and 0.74 (95% CI 0.74 to 0.75), respectively. Fifteen papers reported utilities in head and neck cancers with range 0.29 (95% CI 0.0 to 0.76) to 0.94 (95% CI 0.3 to 1.0). Mean utility reported ranged from 0.5 (95% CI 0.4 to 0.61) to 0.65 (95% CI 0.45 to 0.75) (anal cancer), 0.59 (95% CI 0.54 to 0.64) (vaginal cancer), 0.65 (95% CI 0.60 to 0.70) (vulvar cancer) and 0.79 (95% CI 0.74 to 0.84) (penile cancer). CONCLUSIONS: Differences in values reported from each paper reflect variations in cancer site, disease stages, study population, treatment modality/setting and utility elicitation methods used. As patient management changes over time, corresponding effects on both costs and utility need to be considered to ensure health economic assumptions are up-to-date and closely reflect the case mix of patients.


Subject(s)
Anus Neoplasms/economics , Condylomata Acuminata/economics , Head and Neck Neoplasms/economics , Papillomavirus Infections/economics , Papillomavirus Vaccines/economics , Penile Neoplasms/economics , Respiratory Tract Infections/economics , Vaginal Neoplasms/economics , Vulvar Neoplasms/economics , Anus Diseases/economics , Anus Diseases/prevention & control , Anus Neoplasms/prevention & control , Condylomata Acuminata/prevention & control , Cost-Benefit Analysis , Female , Genital Diseases, Female/economics , Genital Diseases, Female/prevention & control , Genital Diseases, Male/economics , Genital Diseases, Male/prevention & control , Head and Neck Neoplasms/prevention & control , Health Care Costs , Humans , Male , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/therapeutic use , Penile Neoplasms/prevention & control , Quality of Life , Respiratory Tract Infections/prevention & control , United States , Vaginal Neoplasms/prevention & control , Vulvar Neoplasms/prevention & control
11.
BMC Womens Health ; 19(1): 3, 2019 01 07.
Article in English | MEDLINE | ID: mdl-30616555

ABSTRACT

BACKGROUND: HPV DNA is found in almost 80% of VIN/VaIN. Current management is inadequate, with high recurrence rates. Our objective was to review the literature regarding the role of HPV vaccine in secondary prevention and treatment of VIN/VaIN. METHODS: Database searches included Ovid Medline, Embase, Web of Science, The Cochrane Library and Clinicaltrials.gov . Search terms included HPV vaccine AND therapeutic vaccine* AND VIN OR VAIN, published in English with no defined date limit. Searches were carried out with a UCL librarian in March 2018. We included any type of study design using any form of HPV vaccine in the treatment of women with a histologically confirmed diagnosis of VIN/VaIN. We excluded studies of other lower genital tract disease, vulval/vaginal carcinoma and prophylactic use of vaccines. The outcome measures were lesion response to vaccination, symptom improvement, immune response and HPV clearance. RESULTS: We identified 93 articles, 7 studies met our inclusion criteria; these were uncontrolled case series. There were no RCTs or systematic reviews identified. Reduction in lesion size was reported by all 7 studies, symptom relief by 5, HPV clearance by 6, histological regression by 5, and immune response by 6. CONCLUSIONS: This review finds the evidence relating to the use of HPV vaccine in the treatment of women with VIN/VaIN is of very low quality and insufficient to guide practice. Further longitudinal studies are needed to assess its use in prevention of progression to cancer.


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma in Situ/drug therapy , Papillomavirus Vaccines/therapeutic use , Vaginal Neoplasms/drug therapy , Vulvar Neoplasms/drug therapy , Adult , Carcinoma in Situ/prevention & control , Disease Progression , Female , Humans , Middle Aged , Treatment Outcome , Vaginal Neoplasms/prevention & control , Vulvar Neoplasms/prevention & control
13.
Am J Clin Dermatol ; 19(5): 695-706, 2018 Oct.
Article in English | MEDLINE | ID: mdl-29987650

ABSTRACT

Vulvar lichen sclerosus is an important skin disease that is common in women in their 50 s and beyond; however, it can also affect females of any age, including children. If not treated, it has the potential to cause significant and permanent scarring and deformity of the vulvar structure. In addition, if untreated, it is associated with a 2-6% lifetime risk of malignant squamous neoplasia of the vulva. Lichen sclerosus has been considered a difficult to manage condition; however, both serious complications can potentially be prevented with early intervention with topical corticosteroid, suggesting that the course of the disease can be treatment modified.


Subject(s)
Cicatrix/prevention & control , Glucocorticoids/therapeutic use , Vulvar Lichen Sclerosus/drug therapy , Vulvar Neoplasms/prevention & control , Administration, Cutaneous , Cicatrix/etiology , Dermoscopy , Diagnosis, Differential , Female , Humans , Lichenoid Eruptions/diagnosis , Long-Term Care/methods , Psoriasis/diagnosis , Remission Induction/methods , Severity of Illness Index , Skin/diagnostic imaging , Skin/pathology , Time Factors , Treatment Outcome , Vulva/diagnostic imaging , Vulva/pathology , Vulvar Lichen Sclerosus/complications , Vulvar Lichen Sclerosus/diagnosis , Vulvar Lichen Sclerosus/pathology , Vulvar Neoplasms/etiology
14.
Acad Pediatr ; 18(2S): S3-S10, 2018 03.
Article in English | MEDLINE | ID: mdl-29502635

ABSTRACT

Since human papillomavirus (HPV) vaccine was first introduced for females in the United States in 2006, vaccination policy has evolved as additional HPV vaccines were licensed and new data became available. The United States adopted a gender neutral routine HPV immunization policy in 2011, the first country to do so. Vaccination coverage is increasing, although it remains lower than for other vaccines recommended for adolescents. There are various reasons for low coverage, and efforts are ongoing to increase vaccine uptake. The safety profile of HPV vaccine has been well established from 10 years of postlicensure monitoring. Despite low coverage, the early effects of the HPV vaccination program have exceeded expectations.


Subject(s)
Immunization Programs , Oropharyngeal Neoplasms/prevention & control , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/therapeutic use , Uterine Cervical Neoplasms/prevention & control , Vaccination Coverage , Adolescent , Anus Neoplasms/etiology , Anus Neoplasms/prevention & control , Child , Female , Health Policy , Humans , Male , Oropharyngeal Neoplasms/etiology , Papillomavirus Infections/complications , Penile Neoplasms/etiology , Penile Neoplasms/prevention & control , United States , Uterine Cervical Neoplasms/etiology , Vaginal Neoplasms/etiology , Vaginal Neoplasms/prevention & control , Vulvar Neoplasms/etiology , Vulvar Neoplasms/prevention & control
16.
Contemp Clin Trials ; 52: 54-61, 2017 01.
Article in English | MEDLINE | ID: mdl-27777126

ABSTRACT

The 9-valent human papillomavirus (HPV) (9vHPV) vaccine targets four HPV types (6/11/16/18) also covered by the quadrivalent HPV (qHPV) vaccine and five additional types (31/33/45/52/58). Vaccine efficacy to prevent HPV infection and disease was established in a Phase III clinical study in women 16-26years of age. A long-term follow-up (LTFU) study has been initiated as an extension of the Phase III clinical study to assess effectiveness of the 9vHPV vaccine up to at least 14years after the start of vaccination. It includes participants from Denmark, Norway and Sweden and uses national health registries from these countries to assess incidence of cervical pre-cancers and cancers due to the 7 oncogenic types in the vaccine (HPV 16/18/31/33/45/52/58). Incidences will be compared to the estimated incidence rate in an unvaccinated cohort of similar age and risk level. This LTFU study uses a unique design: it is an extension of a Phase III clinical study and also has elements of an epidemiological study (i.e., endpoints based on standard clinical practice; surveillance using searches from health registries); it uses a control chart method to determine whether vaccine effectiveness may be waning. Control chart methods which were developed in industrial and manufacturing settings for process and production monitoring, can be used to monitor disease incidence in real-time and promptly detect a decrease in vaccine effectiveness. Experience from this innovative study design may be applicable to other medicinal products when long-term outcomes need to be assessed, there is no control group, or outcomes are rare.


Subject(s)
Immunogenicity, Vaccine , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/therapeutic use , Precancerous Conditions/prevention & control , Uterine Cervical Dysplasia/prevention & control , Uterine Cervical Neoplasms/prevention & control , Adolescent , Adult , Clinical Trials, Phase III as Topic , Denmark/epidemiology , Female , Follow-Up Studies , Humans , Incidence , Norway/epidemiology , Papillomavirus Infections/epidemiology , Papillomavirus Infections/virology , Papillomavirus Vaccines/immunology , Precancerous Conditions/epidemiology , Precancerous Conditions/virology , Randomized Controlled Trials as Topic , Sweden/epidemiology , Treatment Outcome , Uterine Cervical Neoplasms/epidemiology , Uterine Cervical Neoplasms/virology , Vaginal Neoplasms/epidemiology , Vaginal Neoplasms/prevention & control , Vaginal Neoplasms/virology , Vulvar Neoplasms/epidemiology , Vulvar Neoplasms/prevention & control , Vulvar Neoplasms/virology , Young Adult , Uterine Cervical Dysplasia/epidemiology , Uterine Cervical Dysplasia/virology
17.
Clin Microbiol Infect ; 22 Suppl 5: S125-S127, 2016 Dec 01.
Article in English | MEDLINE | ID: mdl-28034371

ABSTRACT

Since 2006, three vaccines against infections and disease caused by human papillomavirus (HPV) became available in Europe-in 2006 a quadrivalent HPV 6/11/16/18 vaccine, in 2007 a bivalent HPV 16/18 vaccine and in 2015 a nonavalent HPV 6/11/16/18/31/33/45/52/58 vaccine. HPV 16 and 18 are the most oncogenic HPV strains, causing about 70% of cervical and other HPV-related cancers, HPV 6 and 11 cause 85% of all genital warts. The additional types of the polyvalent vaccine account for about 20% of invasive cervical cancer and >35% of pre-cancer. The potential differences between these vaccines caused some debate. All three vaccines give a robust and long-lasting protection against the strains in the various vaccines. The promise of cross-protection against other types (i.e. HPV 31/33/45) and hence a broader cancer protection was not fulfilled because these observations were confounded by the vaccine efficacy against the vaccine types. Furthermore, cross-protection was not consistent over various studies, not durable and not consistently seen in the real world experience. The protection against disease caused by oncogenic HPV strains was not compromised by the protection against low-risk types causing genital warts. The most effective cancer protection to date can be expected by the nonavalent vaccine, data indicate a 97% efficacy against cervical and vulvovaginal pre-cancer caused by these nine HPV types.


Subject(s)
Condylomata Acuminata/prevention & control , Papillomaviridae/immunology , Papillomavirus Vaccines/immunology , Uterine Cervical Neoplasms/virology , Vulvar Neoplasms/virology , Female , Humans , Uterine Cervical Neoplasms/prevention & control , Vulvar Neoplasms/prevention & control
18.
Br J Hosp Med (Lond) ; 77(10): 565-568, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27723397
19.
Obstet Gynecol ; 128(4): 937-938, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27661648

ABSTRACT

Vulvar intraepithelial neoplasia (VIN) is an increasingly common problem, particularly among women in their 40s. Although spontaneous regression has been reported, VIN should be considered a premalignant condition. Immunization with the quadrivalent or 9-valent human papillomavirus vaccine, which is effective against human papillomavirus genotypes 6, 11, 16, and 18, and 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively, has been shown to decrease the risk of vulvar high-grade squamous intraepithelial lesion (HSIL) (VIN usual type) and should be recommended for girls aged 11-12 years with catch-up through age 26 years if not vaccinated in the target age. There are no screening strategies for the prevention of vulvar cancer through early detection of vulvar HSIL (VIN usual type). Detection is limited to visual assessment with confirmation by histopathology when needed. Treatment is recommended for all women with vulvar HSIL (VIN usual type). Because of the potential for occult invasion, wide local excision should be performed if cancer is suspected, even if biopsies show vulvar HSIL. When occult invasion is not a concern, vulvar HSIL (VIN usual type) can be treated with excision, laser ablation, or topical imiquimod (off-label use). Given the relatively slow rate of progression, women with a complete response to therapy and no new lesions at follow-up visits scheduled 6 months and 12 months after initial treatment should be monitored by visual inspection of the vulva annually thereafter.


Subject(s)
Carcinoma in Situ/prevention & control , Vulvar Neoplasms/prevention & control , Carcinoma in Situ/diagnosis , Carcinoma in Situ/therapy , Female , Gynecology , Humans , Practice Patterns, Physicians' , Vulvar Neoplasms/diagnosis , Vulvar Neoplasms/therapy
20.
Obstet Gynecol ; 128(4): e178-e182, 2016 10.
Article in English | MEDLINE | ID: mdl-27661656

ABSTRACT

Vulvar intraepithelial neoplasia (VIN) is an increasingly common problem, particularly among women in their 40s. Although spontaneous regression has been reported, VIN should be considered a premalignant condition. Immunization with the quadrivalent or 9-valent human papillomavirus vaccine, which is effective against human papillomavirus genotypes 6, 11, 16, and 18, and 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively, has been shown to decrease the risk of vulvar high-grade squamous intraepithelial lesion (HSIL) (VIN usual type) and should be recommended for girls aged 11-12 years with catch-up through age 26 years if not vaccinated in the target age. There are no screening strategies for the prevention of vulvar cancer through early detection of vulvar HSIL (VIN usual type). Detection is limited to visual assessment with confirmation by histopathology when needed. Treatment is recommended for all women with vulvar HSIL (VIN usual type). Because of the potential for occult invasion, wide local excision should be performed if cancer is suspected, even if biopsies show vulvar HSIL. When occult invasion is not a concern, vulvar HSIL (VIN usual type) can be treated with excision, laser ablation, or topical imiquimod (off-label use). Given the relatively slow rate of progression, women with a complete response to therapy and no new lesions at follow-up visits scheduled 6 months and 12 months after initial treatment should be monitored by visual inspection of the vulva annually thereafter.


Subject(s)
Carcinoma in Situ/therapy , Vulvar Neoplasms/therapy , Antineoplastic Agents/therapeutic use , Carcinoma in Situ/classification , Carcinoma in Situ/diagnosis , Carcinoma in Situ/prevention & control , Female , Humans , Laser Therapy , Vulvar Neoplasms/classification , Vulvar Neoplasms/diagnosis , Vulvar Neoplasms/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL
...